MarketCap
Facebook
X
Telegram
Equillium EV | EQ
EV Jährlich Equillium
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 91.1 M | 61.3 M | 89.5 M | 8.28 M | 77.1 M | 133 M | 83.4 M | 74.3 M | 9.4 M | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 133 M | 8.28 M | 69.7 M |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Neos Therapeutics, Inc.
NEOS
|
-14.1 M | - | -2.54 % | $ 57.2 M |  USA |
 |
Odonate Therapeutics, Inc.
ODT
|
5.24 B | - | -3.18 % | $ 58.5 M | USA |
 |
Orphazyme A/S
ORPH
|
284 M | - | -2.25 % | $ 31.3 M |  Danmark |
 |
Osmotica Pharmaceuticals plc
OSMT
|
6.61 B | - | -10.74 % | $ 89.9 M | USA |
 |
Pandion Therapeutics, Inc.
PAND
|
29.5 K | - | - | $ 1.77 B | USA |
 |
Xenetic Biosciences
XBIO
|
-2.54 M | $ 1.87 | 3.68 % | $ 3.18 M | USA |
 |
Viridian Therapeutics
VRDN
|
2.95 B | $ 31.22 | 1.17 % | $ 3.18 B | USA |
 |
Translate Bio, Inc.
TBIO
|
1.43 B | - | - | $ 2.81 B | USA |
 |
Trillium Therapeutics Inc.
TRIL
|
83.6 M | - | - | $ 1.94 B |  Canada |
 |
Urovant Sciences Ltd.
UROV
|
37.4 B | - | - | $ 532 M |  Britain |
 |
Acceleron Pharma Inc.
XLRN
|
-182 M | - | - | $ 10.9 B | USA |
 |
Zealand Pharma A/S
ZEAL
|
866 M | - | 0.52 % | $ 821 M | Danmark |
 |
Zogenix, Inc.
ZGNX
|
18.2 B | - | -4.97 % | $ 664 M | USA |
 |
Yunhong International
ZGYH
|
18.2 B | - | 0.10 % | $ 92.2 M |  China |
 |
ZIOPHARM Oncology, Inc.
ZIOP
|
96.3 B | - | -7.58 % | $ 264 M | USA |
 |
Vanda Pharmaceuticals
VNDA
|
435 M | $ 4.17 | 2.08 % | $ 246 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
58.9 M | $ 3.88 | 10.23 % | $ 41.3 M | USA |
 |
Leap Therapeutics
LPTX
|
-4.36 M | - | 368.57 % | $ 41.9 M | USA |
 |
Zymeworks
ZYME
|
783 M | $ 29.06 | -7.64 % | $ 1.5 B | Canada |
 |
Adial Pharmaceuticals
ADIL
|
-3.17 M | $ 3.15 | -35.42 % | $ 2.11 M | USA |
 |
ADMA Biologics
ADMA
|
3.84 B | $ 13.19 | 4.1 % | $ 3.14 B | USA |
 |
Cortexyme
CRTX
|
123 M | - | -1.05 % | $ 67.1 M | USA |
 |
Burford Capital Limited
BUR
|
5.73 B | $ 3.65 | 0.14 % | $ 800 M | Britain |
 |
Daré Bioscience
DARE
|
21.8 M | $ 0.71 | 2.5 % | $ 7.94 M | USA |
 |
Fate Therapeutics
FATE
|
140 M | $ 1.6 | -9.6 % | $ 190 M | USA |
 |
Greenwich LifeSciences
GLSI
|
386 M | $ 16.12 | 0.31 % | $ 218 M | USA |
 |
Halozyme Therapeutics
HALO
|
12 B | $ 101.68 | -1.26 % | $ 12.2 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
12.4 B | $ 15.09 | -1.92 % | $ 13 B | China |
 |
Aptorum Group Limited
APM
|
8.14 M | - | - | $ 5.72 M | China |
 |
iBio
IBIO
|
98.5 M | $ 0.82 | 5.55 % | $ 85.3 M | USA |
 |
Kodiak Sciences
KOD
|
2.01 B | $ 109.34 | 1.18 % | $ 5.82 B | USA |
 |
Karyopharm Therapeutics
KPTI
|
341 M | $ 0.02 | -56.5 % | $ 219 | USA |
 |
FSD Pharma
HUGE
|
4.15 M | - | 5743.5 % | $ 69.7 M | Canada |
 |
BioAtla
BCAB
|
52.3 M | $ 1.74 | 0.64 % | $ 102 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
2.48 B | - | - | $ 3.85 B | USA |
 |
UroGen Pharma Ltd.
URGN
|
1.12 B | $ 26.14 | 3.24 % | $ 1.26 B |  Israel |
 |
Catalyst Biosciences
CBIO
|
986 M | $ 14.79 | 6.25 % | $ 1.32 B | USA |
 |
ARCA biopharma
ABIO
|
-30.2 M | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
-14.2 M | - | 4.01 % | $ 150 M | Canada |
 |
ADiTx Therapeutics
ADTX
|
9.4 M | - | - | $ 374 | USA |
 |
Aeterna Zentaris
AEZS
|
10.3 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
3.93 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-23.2 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
9.53 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aileron Therapeutics
ALRN
|
4.02 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-55.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
3.01 B | - | - | $ 5.18 B | USA |
 |
Athira Pharma
ATHA
|
-4.92 M | - | - | $ 269 M | USA |
 |
AVROBIO
AVRO
|
-244 M | - | 1083.1 % | $ 745 M | USA |
 |
AstraZeneca PLC
AZN
|
59.6 B | - | - | $ 96.9 B | Britain |